Emcure Pharmaceuticals Limited has announced the successful completion of a strategic acquisition in the Canadian market, with its step-down subsidiary acquiring a cosmetics and dermatological products company for CAD $5.05 million. The transaction was executed on April 01, 2026, and was immediately followed by an amalgamation to consolidate the group's Canadian operations.

Acquisition Details

Mantra Pharma Inc., a step-down subsidiary of Emcure Pharmaceuticals and subsidiary of Marcan Pharmaceuticals Inc., entered into a share purchase agreement to acquire 100% of the issued and outstanding shares of Cutimed Inc. The acquisition transforms Cutimed into a step-down wholly owned subsidiary of the company.

Target Company Profile

Cutimed Inc. is a Quebec-incorporated company that has been operating in the cosmetics and personal care products sector since 2011. The company specializes in developing and commercializing dermatological products, including creams, cleansers, and lip care products, primarily serving the Canadian market.

Note: Cutimed's financial year runs from September 1st to August 30th

Immediate Amalgamation

Following the acquisition, Cutimed was amalgamated with Mantra Pharma Inc. effective April 01, 2026, using the short-form amalgamation procedure under Quebec's Business Corporations Act. This amalgamation involved two wholly owned subsidiaries of Emcure Pharmaceuticals and was conducted on an arm's length basis.

Strategic Rationale

The acquisition and subsequent amalgamation serve multiple strategic objectives for the Emcure group. The transaction strengthens the group's portfolio in Canadian dermatological and cosmetic product segments while supporting long-term growth strategy in the Canadian market. The consolidation of Canadian operations aims to achieve operational efficiency and administrative efficiencies through integrated operations, aligning with the core business activities of the pharmaceutical group.

Regulatory Compliance

The transaction required completion of requisite compliances in accordance with applicable Canadian laws and customary conditions. No specific government approvals were required for the acquisition. The transaction does not constitute a related party transaction, as neither the promoter, promoter group, nor group companies had any prior interest in Cutimed. Additionally, there is no change in the shareholding pattern of Emcure Pharmaceuticals Limited as a result of this transaction.

Emcure Pharmaceuticals Limited has issued a postal ballot notice dated March 24, 2026, seeking shareholder approval for the appointment of Mr. C S Muralidharan as an Independent Director. The company published newspaper advertisements on March 25, 2026, confirming the electronic dispatch of the postal ballot notice and has engaged MUFG Intime India Private Limited to provide e-voting facilities.

Proposed Director Appointment

The postal ballot seeks approval for the appointment of Mr. C S Muralidharan (DIN: 00014740 and IDDB Registration Number: IDDB-DI-202506-074680) as an Independent Director of the company. The appointment is proposed for a term of three consecutive years with effect from April 01, 2026, and he will not be liable to retire by rotation.

Director's Professional Background

Mr. Muralidharan brings extensive corporate experience to the board. He is a Cost & Management Accountant with a Master's degree in commerce and has completed the Executive Program in General Management from Booth School of Business, University of Chicago. His professional experience spans 40 years across hydro-carbon and pharmaceutical sectors.

His career includes senior leadership positions across multiple entities in India, Asia and Europe. He has previously worked with organizations including Indian Oil Corporation Limited, Ranbaxy Group, Lupin Limited, Matrix Laboratories Limited, Watson Group, and Sun Pharmaceutical Industries Limited where he served as Group Chief Financial Officer.

E-Voting Process and Timeline

The company has implemented a comprehensive e-voting process for the postal ballot, with specific timelines established for shareholder participation.

Newspaper Advertisement and Regulatory Compliance

Pursuant to Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company published newspaper advertisements on March 25, 2026, in "Financial Express" (English - all editions) and "Loksatta" (Marathi - Pune edition). The advertisements confirmed the completion of electronic dispatch of the postal ballot notice dated March 24, 2026.

The postal ballot notice complies with General Circular No. 03/2025 dated September 22, 2025, issued by the Ministry of Corporate Affairs and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The Board of Directors approved Mr. Muralidharan's appointment at its meeting held on March 09, 2026, based on the recommendation of the Nomination and Remuneration Committee.

Scrutinizer and Results Declaration

The company has appointed Ms. Ashwini Inamdar (Membership No. FCS 9409, CP No. 11226) and alternatively Mr. Atul Mehta (Membership No. FCS 5782, CP No. 2486), Partners of M/s. Mehta & Mehta, Practicing Company Secretaries, as Scrutinizers for conducting the postal ballot process. The results will be declared within two working days from the conclusion of e-voting and displayed on the company's website, stock exchange websites, and MUFG Intime's website.